Sam-A Pharm. Co., Ltd
Financials
Valuation Metrics
Sam-A Pharm. Co., Ltd's Market Cap is ₩891B. At end of 2025 it was ₩1001B. Ranked #1350 of 2,421 in KR market (top 56%), #754 of 1,640 on KOSDAQ (top 46%), #146 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 63%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 89.05B KRW | KR#1,350/2,421 Sec#146/231 |
| Revenue | 72.28B KRW | KR#1,603/2,421 Sec#104/231 |
| Net Income | 10.55B KRW | KR#953/2,421 Sec#60/231 |
| Total Assets | 249.78B KRW | KR#1,140/2,421 Sec#79/231 |
| Net Assets | 229.65B KRW | KR#867/2,421 Sec#60/231 |
| Employees | 316 | KR#761/2,421 Sec#66/231 |
| Value | ||
| P/E | 8.44x | KR#696/2,421 Sec#31/231 |
| P/B | 0.39x | KR#535/2,421 Sec#17/231 |
| P/S | 1.23x | KR#1,513/2,421 Sec#86/231 |
| EV/EBITDA | 13.14x | KR#769/2,421 Sec#42/231 |
| FCF Yield | 10.50% | KR#588/2,421 Sec#23/231 |
| Profitability | ||
| ROE | 4.59% | KR#1,151/2,421 Sec#80/231 |
| ROA | 4.22% | KR#830/2,421 Sec#67/231 |
| Op. Margin | 7.59% | KR#691/2,421 Sec#55/231 |
| Revenue Growth | -12.40% | KR#1,979/2,421 Sec#181/231 |
| Earnings Growth | -31.27% | KR#986/2,421 Sec#63/231 |
| Financial Health | ||
| Debt Ratio | 8.77% | KR#114/2,421 Sec#23/231 |
| Total Debt | 2.62B KRW | KR#1,881/2,421 Sec#182/231 |
| FCF | 9.35B KRW | KR#725/2,421 Sec#40/231 |
| Cash | 19.64B KRW | KR#1,266/2,421 Sec#93/231 |
| Current Ratio | 10.11x | KR#96/2,421 Sec#22/231 |
| Net Debt/EBITDA | -3.10x | KR#154/2,421 Sec#4/231 |
| Dividend | ||
| Div. Yield | 6.07% | KR#183/2,421 Sec#3/231 |
| Div. Growth | 6.25% | KR#649/2,421 Sec#35/231 |
| Performance | ||
| 1Y Return | -18.91% | KR#1,240/2,421 Sec#84/231 |
| 1M Return | 3.71% | KR#866/2,421 Sec#62/231 |
| From 52W High | -20.02% | KR#258/2,421 Sec#11/231 |
| 1Y MDD | -30.49% | KR#264/2,421 Sec#16/231 |
| Trading | ||
| Volume | 664 shares | KR#2,351/2,421 Sec#226/231 |
| Trading Value | 9.3M KRW | KR#2,285/2,421 Sec#217/231 |
| Foreign Own. | 2.81% | KR#1,350/2,421 Sec#125/231 |
| Per Share | ||
| EPS | 1,655 KRW | KR#510/2,421 Sec#35/231 |
| BPS | 36,051 KRW | KR#326/2,421 Sec#20/231 |
Company Info
Sama Pharmaceutical, founded as Bogun Pharmaceutical Laboratory in 1945 and incorporated in 1973, was listed on KOSDAQ in 2000. It manufactures and sells a wide range of pharmaceuticals, including respiratory, antibiotic, dermatological, and digestive system drugs, with key products like Citoos, Codenal, Hebron, and Setofen. The company completed its Munmak factory as a KGMP pharmaceutical production facility in 2009 and continues to develop differentiated generic products through new drug and new product research and development. Sama Pharmaceutical is headquartered in Wonju-si, Gangwon-do.